Education
About Us
Working with TipRanks
Follow Us
Anatara Lifesciences Ltd (AU:ANR)
ASX:ANR
ANR Stock Chart & Stats
AU$0.01
<AU$0.01(3.85%)
At close: 4:00 PM EST
AU$0.01
<AU$0.01(3.85%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.06
Previous CloseN/A
Volume35.84K
Average Volume (3M)759.89K
Market Cap
AU$3.14M
Enterprise ValueAU$2.24M
Total Cash (Recent Filing)AU$101.36K
Total Debt (Recent Filing)AU$407.42K
Price to Earnings (P/E)―
Beta0.48
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding315,950,780
10 Day Avg. Volume1,527,300
30 Day Avg. Volume759,886
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)1.91
Price to Sales (P/S)1.06
P/FCF Ratio-0.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clear Product Focus (GaRP)A single, well-defined lead candidate (GaRP) gives the company a focused R&D and regulatory pathway. Specialization in an orally delivered GI therapeutic supports targeted clinical development, intellectual property consolidation and clearer partnering or licensing conversations over the medium term.
Early Commercial Traction: Revenue ReboundA large year-over-year revenue rebound indicates initial market uptake or milestone-related receipts, providing evidence of demand or commercial progress. Sustained top-line growth from this base can materially improve unit economics and reduce reliance on financing if continued over the next several quarters.
End-to-end Development And Commercial PlanningMaintaining capabilities across development, clinical validation, regulatory readiness and partnering/commercial planning de-risks program progression. This end-to-end approach increases options (internal launch, partnerships, or licensing) and supports durable execution toward market entry and revenue scale.
Bears Say
Negative Gross Profit And Deep LossesNegative gross profit means core product costs exceed revenues, indicating underlying unit economics are unsustainable today. Large net losses and very negative margins erode equity, prolong the path to self-sustaining operations and require structural improvements in pricing, cost base or product mix to reach profitability.
Worsening Cash Burn And Negative Cash FlowPersistent negative operating and free cash flow show the business cannot self-fund development and commercial activities. Rising cash burn increases dependency on external financing, raising dilution risk and potentially constraining R&D or commercial investments if capital access tightens over the next several quarters.
Deteriorating Balance-sheet FlexibilityA sharp fall in equity alongside rising debt reduces financial flexibility and increases leverage risk. Weaker balance-sheet capacity limits the company’s ability to absorb setbacks, negotiate favourable partnerships, or invest for growth without further dilutive or costly financing, heightening medium-term execution risk.
Anatara Lifesciences Ltd News
ANR FAQ
What was Anatara Lifesciences Ltd’s price range in the past 12 months?
Anatara Lifesciences Ltd lowest share price was <AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is Anatara Lifesciences Ltd’s market cap?
Anatara Lifesciences Ltd’s market cap is AU$3.14M.
When is Anatara Lifesciences Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Anatara Lifesciences Ltd’s earnings last quarter?
Currently, no data Available
Is Anatara Lifesciences Ltd overvalued?
According to Wall Street analysts Anatara Lifesciences Ltd’s price is currently Overvalued.
Does Anatara Lifesciences Ltd pay dividends?
Anatara Lifesciences Ltd does not currently pay dividends.
What is Anatara Lifesciences Ltd’s EPS estimate?
Anatara Lifesciences Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anatara Lifesciences Ltd have?
Anatara Lifesciences Ltd has 315,950,780 shares outstanding.
What happened to Anatara Lifesciences Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Anatara Lifesciences Ltd?
Currently, no hedge funds are holding shares in AU:ANR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anatara Lifesciences Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ANR Sentiment 85%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$40.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
―
20 days / 200 days
Momentum
-79.31%
12-Months-Change
Fundamentals
Return on Equity
-205.70%
Trailing 12-Months
Asset Growth
-31.29%
Trailing 12-Months
Company Description
Anatara Lifesciences Ltd
Anatara Lifesciences Limited engages in the research, development, and commercializing of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and 3FDC for the treatment of anxiety, stress, or depression. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry water. Anatara Lifesciences Limited was incorporated in 2010 and is based in Carlton, Australia.
Technical Analysis
AnteoTech Ltd
―
Regeneus Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Hexima Ltd
―
Options Prices
Currently, No data available
---